Free Trial
→ The case for $20,000 gold before year end (From Stansberry Research) (Ad)tc pixel
OTCMKTS:CYDY

CytoDyn Q1 2027 Earnings Report

CytoDyn logo
$0.20 0.00 (-0.25%)
As of 10/5/2026 03:59 PM Eastern
ProfileEarnings History

CytoDyn EPS Results

Actual EPS
N/A
Consensus EPS
-$0.05
Beat/Miss
N/A
One Year Ago EPS
N/A

CytoDyn Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CytoDyn Announcement Details

Quarter
Q1 2027
Date
10/8/2026
Time
N/A
Conference Call Date
Wednesday, October 14, 2026
Conference Call Time
9:30AM ET

Conference Call Resources

CytoDyn Earnings Headlines

CytoDyn (CYDY) Set to Announce Quarterly Earnings on Thursday
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31071879
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
September 15, 2026  |  financialpost.comF
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
 |  Behind the Markets (Ad)
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362079/0/en/cytodyn-inc-to-present-at-the-life-sciences-investor-forum-on-september-17th.html
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354141/19782/en/cytodyn-closes-16-5-million-financing-to-fund-continued-development-of-leronlimab.html
Kessler Topaz Meltzer & Check, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of CytoDyn Inc. common stock
July 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kessler-topaz-meltzer--check-llp-announces-proposed-class-action-settlement-on-behalf-of-purchasers-of-cytodyn-inc-common-stock-302817255.html
See More CytoDyn Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CytoDyn? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytoDyn and other key companies, straight to your email.

About CytoDyn

CytoDyn (OTCMKTS:CYDY) is a biotechnology company focused on the development of leronlimab, an investigational monoclonal antibody that targets CCR5, a receptor involved in immune-cell signaling and the movement of certain cells through the body. The company’s research has explored potential applications in infectious diseases, oncology and inflammatory conditions.

Leronlimab, also known as PRO 140, has been studied primarily as a potential treatment for HIV infection, including in combination with existing antiretroviral therapies. CytoDyn has also evaluated the drug in investigational programs involving cancer and other diseases. Leronlimab is not an approved product, and the company’s programs remain subject to clinical, regulatory and scientific development requirements.

CytoDyn is headquartered in Vancouver, Washington, and has historically operated as a development-stage biotechnology company rather than a commercial pharmaceutical business. The company’s activities have centered on clinical research, regulatory engagement and potential partnering related to leronlimab. Dr. Jacob Lalezari has served in a senior leadership role, including as chief executive officer, and has been associated with the company’s HIV development efforts.

View CytoDyn Profile
Earnings Tools